Bisphosphonates and other bone agents for breast cancer.


BACKGROUND Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab, inhibit key pathways in the vicious cycle of bone metastases. OBJECTIVES To assess the effect of bisphosphonates on skeletal-related events (SREs… (More)
DOI: 10.1002/14651858.CD003474.pub3


21 Figures and Tables

Cite this paper

@article{Wong2012BisphosphonatesAO, title={Bisphosphonates and other bone agents for breast cancer.}, author={Matthew H F Wong and Martin Richard Stockler and Nick Pavlakis}, journal={The Cochrane database of systematic reviews}, year={2012}, volume={10}, pages={CD003474} }